The Hemolung RAS provides Respiratory Dialysis®, a simple, minimally invasive form of ECCO2R which serves as an alternative or supplement to mechanical ventilation in critically ill patients suffering from acute respiratory failure. Indications for the device include cases of acute exacerbation of chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS). Following a successful clinical trial in
“These new funds will allow us to accelerate the global commercialization of the Hemolung technology,” said
“The past year has been an exciting time for ALung, and we appreciate the support of our investors,” added
About the Hemolung RAS
The Hemolung RAS is a dialysis-like alternative or supplement to mechanical ventilation. The system provides Respiratory Dialysis®, a simple, minimally invasive form of extracorporeal carbon dioxide removal (ECCO2R) and has indications for use in patients with acute respiratory distress syndrome (ARDS) and acute exacerbation of chronic obstructive pulmonary disease (COPD).
About ALung Technologies
For more information, please visit http://www.alung.com.
This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.
Vice President of Marketing and Clinical Affairs